Thromboreductin Adverse Reactions

The following adverse events occurred during therapy with Anagrelide: headache, palpitations, diarrhoea, weakness, oedema, nausea, abdominal pain, dizziness, pain, dyspnoea, flatulence, vomiting, fever, rash, chest pain, anorexia, tachycardia, pharyngitis, malaise, cough, paresthesia, back pain, pruritus, dyspepsia. Most adverse events occurred during treatment initiation, were of minor intensity and diminished during ongoing therapy. Adverse events tended to decrease in number and intensity with time. In addition, adverse events occurred which involved the following organs: cardiovascular system, gastrointestinal tract, haematopoietic and lymphatic system, liver, musculoskeletal system, nervous system, respiratory system, dermatological and appendages system, sensory system, urogenital system, flu and flu-like symptoms, dehydration.
In case of headache (this occurs mainly upon treatment initiation) a pain medication like acetaminophen should be prescribed. In case of diarrhoea, lactase should be prescribed. Lactose intolerance should be considered.
The following severe adverse events were observed during therapy with Anagrelide: heart failure, myocardial infarction, cardiomyopathy, heart block, atrial fibrillation, cerebrovascular events, pericarditis, pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension, pancreatitis, gastrointestinal ulcers, seizures.